Tetrabenazine (Racemate) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2).(1) The reference for administration is 0.25-0.75 mg/kg IP(2) Injections of tetrabenazine into accumbens core also reduced FR5 lever pressing and increased chow intake. (3) Tetrabenazine (Racemate) reduced extracellular DA and altered DARPP-32 signaling in both substance-P- and enkephalin-containing accumbens neurons. (4) Tetrabenazine (Racemate) inhibits locomotor activity and produces hypothermia upon systemic administration in rats and mice.
[1]. Nunes EJ et al. Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci. 2013 Dec 4;33(49):19120-30. [2]. Podurgiel SJ et al. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor. Neuroscience. 2013 Oct 10;250:507-19. [3]. Reches A et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther. 1983 Jun;225(3):515-21.